Compare HURN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | NVCR |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 1.5B |
| IPO Year | 2004 | 2015 |
| Metric | HURN | NVCR |
|---|---|---|
| Price | $179.26 | $14.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $206.75 | $28.42 |
| AVG Volume (30 Days) | 142.2K | ★ 1.4M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | ★ 5.98 | N/A |
| Revenue | ★ $1,618,977,000.00 | $642,269,000.00 |
| Revenue This Year | $14.19 | $9.75 |
| Revenue Next Year | $9.49 | $5.62 |
| P/E Ratio | $29.76 | ★ N/A |
| Revenue Growth | ★ 12.67 | 11.17 |
| 52 Week Low | $120.25 | $10.70 |
| 52 Week High | $182.71 | $30.78 |
| Indicator | HURN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 67.00 |
| Support Level | $169.02 | $12.88 |
| Resistance Level | $182.68 | $13.64 |
| Average True Range (ATR) | 4.20 | 0.50 |
| MACD | -0.64 | 0.12 |
| Stochastic Oscillator | 74.76 | 93.10 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.